Dr Curtis Lachowiez speaks to ecancer about the interim results of a phase 1b/2 study he presented at the virtual ASH 2020 meeting on the use of venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or relapsed/refractory AML.
He explains that there is more and more data that suggests incorporating venetoclax into treatment regimens can lead to more robust responses.
Dr Lachowiez reports from the phase 1b safety portion of the trial that there was a prolonged myelosuppression which led to the dose being altered to a safer level.
He explains that the outcomes were favourable with newly diagnosed patients seeing a composite complete response rate of around 90%.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.